Compound deep-dive Semaglutide explained: the GLP-1 receptor agonist that defined the modern era. A 31-amino-acid synthetic peptide developed by Novo Nordisk. Three small engineering changes to the native human GLP-1 backbone produced an 11000-fold half-life increase. The molecule that brought…
Compound deep-dive TB-500 explained: the Thymosin Beta-4 fragment. A synthetic peptide built around the conserved actin-binding motif of Thymosin Beta-4. Forty years of literature from Goldstein, Kleinman and the wider thymosin field. The compound that most suppliers leave fuzzy about…
Compound deep-dive BPC-157 explained: the most-researched peptide in the catalogue. A 15-amino-acid fragment derived from a Body Protection Compound first isolated from human gastric juice. Characterised at the University of Zagreb from 1991 onwards. Over 200 peer-reviewed papers. The unusual…
Compound deep-dive Tirzepatide explained: the dual GIP and GLP-1 receptor agonist. A 39-amino-acid synthetic peptide developed by Eli Lilly that simultaneously activates both incretin receptors. The first twincretin to reach late-stage clinical development. Beat semaglutide on every endpoint of the…
Compound deep-dive Retatrutide explained: the triple-receptor agonist. A 39-amino-acid synthetic peptide developed by Eli Lilly that activates three receptors at once: GIP, GLP-1, and glucagon. The first trinity agonist to publish a full Phase 2 dataset. The 12 mg arm…
Compound deep-dive Selank: the underrated Russian anxiolytic peptide. A seven-amino-acid analogue of tuftsin. Thirty years of Russian-language clinical and preclinical research literature. Approved as a drug in Russia. Almost completely absent from Western research conversations. Here is everything the literature…
Compound deep-dive GHK-Cu explained: the blue copper peptide. Glycyl-histidyl-lysine bound to a single copper ion. First isolated from human plasma by Pickart in 1973. Fifty years of peer-reviewed research, a vivid cobalt-blue colour that tells you whether the synthesis is…
Research comparison Semaglutide vs Retatrutide A side-by-side comparison of Semaglutide – a single-target GLP-1 receptor agonist – and Retatrutide, a triple agonist at the GLP-1, GIP and glucagon receptors. Mechanism, sequence, pharmacokinetics, lab handling, and how researchers select between them. Both compounds are supplied…
Industry reality How to spot a fake research peptide supplier (UK 2026) A 12-point checklist for vetting any UK research-peptide supplier, written by a UK supplier. Including us scoring ourselves transparently against the same criteria. By Joe, founder· Published 29…
